Regulatory T cells maintain immune balance by actively restraining excessive or misdirected responses. Shimon Sakaguchi Kyoto University first defined a population of suppressive CD25 positive T cells, and subsequent work by Alexander Rudensky Memorial Sloan Kettering Cancer Center established the transcription factor FOXP3 as the master regulator that programs these cells. Clinical observations of FOXP3 mutations producing severe autoimmunity in humans provide strong evidence that regulatory T cells are essential for self-tolerance.
Cellular and molecular mechanisms
Regulatory T cells use multiple, often overlapping mechanisms to suppress immune responses. One central strategy is consumption of growth signals. By expressing high levels of the IL-2 receptor alpha chain CD25 they act as cytokine sinks, limiting IL-2 availability for conventional T cells and thereby constraining their proliferation. Contact-dependent regulation is another major axis. Work by Ethan Shevach National Institute of Allergy and Infectious Diseases and others highlights CTLA-4 expressed on regulatory T cells as a molecule that strips or downregulates costimulatory molecules CD80 and CD86 on antigen presenting cells, reducing their capacity to activate naïve T cells.
Secreted inhibitory cytokines form a complementary pathway. Regulatory T cells produce IL-10, TGF-beta, and IL-35, which directly inhibit effector T cell function and modulate antigen presenting cells toward a tolerogenic state. Some studies associated with Jeffrey Bluestone University of California San Francisco illustrate how these cytokines contribute to suppression in tissues such as the gut and pancreas. Metabolic disruption is a further tactic: expression of enzymes CD39 and CD73 converts extracellular ATP to adenosine and creates an immunosuppressive milieu. In selected contexts regulatory T cells can also kill target cells through granzyme and perforin pathways, showing functional breadth that is context dependent.
Physiological relevance and clinical consequences
The consequences of regulatory T cell activity are broad and context specific. In healthy tissues they prevent autoimmunity, support tolerance to commensal microbes in the gut, and contribute to maternal-fetal tolerance during pregnancy. Alexander Rudensky Memorial Sloan Kettering Cancer Center and other groups have emphasized the importance of tissue-adapted regulatory T cells that acquire unique phenotypes and functions shaped by local environmental signals and the microbiome. Conversely, the same suppressive capacity can limit beneficial immune responses against chronic infections and tumors. James Allison University of Texas MD Anderson Cancer Center and colleagues demonstrated that manipulating checkpoints such as CTLA-4 can relieve suppression and boost anti-tumor immunity, a principle that underlies modern cancer immunotherapy while also risking autoimmunity.
Understanding how regulatory T cells are specified, maintained, and sometimes destabilized is critical for translating basic biology into therapies. Researchers are exploring ways to enhance regulatory T cell function for autoimmune and transplant tolerance and to inhibit their activity in cancer. These translational directions reflect decades of work by leading immunologists and institutions and point to the central role of regulatory T cells in shaping human health across cultural and environmental contexts where infections, microbiota composition, and medical practices vary.